Smooth muscle K Ca 3.1 limits plaque progression and alters plaque composition in mice

Increased expression of KCa3.1 has been found in vascular smooth muscle cells (SMC), macrophages, and T cells in atherosclerotic lesions from humans and mice. While the efficacy of pharmacological inhibition and global silencing of KCa3.1 in limiting atherosclerosis has been demonstrated, the relative cell-specific contributions of KCa3.1 have not been determined. Therefore, we generated a smooth muscle (SMC) specific inducible KCa3.1-/- mouse with global Apoe-/- knockout (iSMKO) and assessed lesion development in the brachiocephalic artery (BCA) of tamoxifen vs. vehicle injected iSMKO mice on a Western diet (WD) for 15 or 40 weeks. In BCAs of iSMKO mice, lesion size and relative stenosis were increased and lumenal area decreased compared to vehicle injected mice. Additionally, iSMKO mice exhibited a significant reduction in SMC and collagen content at 15 weeks and 40 weeks, while macrophage content increased at 40 weeks. RNAseq analysis of BCA samples from tamoxifen and vehicle injected iSMKO mice prior to WD feeding (baseline) indicated increased mitochondrial function and PPAR-dependent signaling, similar to that found in prior studies of global KCa3.1 silencing. However, following 15 weeks of WD and induction of disease, these differences were no longer observed. Overall, this study provides the first cell-specific silencing of KCa3.1 to elucidate the contribution of KCa3.1 in smooth muscle to prior observations of KCa3.1 silencing. Our findings reveal both a beneficial role of SMC KCa3.1 in limiting plaque size and macrophage infiltration, and a potentially detrimental effect of reducing plaque SMC and collagen content. Combined with previous studies, this raises caution in the use of pharmacological KCa3.1 inhibitors in atherosclerosis and highlights the need for cell-specific targeting of KCa3.1 in optimizing potential therapies.

Authors

Institutions

Publication Details

Journal
bioRxiv (Cold Spring Harbor Laboratory)
Published
2026-11-16
DOI
https://doi.org/10.64898/2026.11.12.766210
Primary Topic
Atherosclerosis and Cardiovascular Diseases
Type
preprint

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Smooth muscle K Ca 3.1 limits plaque progression and alters plaque composition in mice

Perwez Alam, Douglas K. Bowles, Shawn B. Bender, Darla L. Tharp et al.
2 links
bioRxiv (Cold Spring Harbor Laboratory)
Atherosclerosis and Cardiovascular Diseases
preprint

Smooth muscle K Ca 3.1 limits plaque progression and alters plaque composition in mice

Perwez Alam, Douglas K. Bowles, Shawn B. Bender, Darla L. Tharp, Hunter J Bowles, Hieu Bui
preprint en

Abstract

Increased expression of KCa3.1 has been found in vascular smooth muscle cells (SMC), macrophages, and T cells in atherosclerotic lesions from humans and mice. While the efficacy of pharmacological inhibition and global silencing of KCa3.1 in limiting atherosclerosis has been demonstrated, the relative cell-specific contributions of KCa3.1 have not been determined. Therefore, we generated a smooth muscle (SMC) specific inducible KCa3.1-/- mouse with global Apoe-/- knockout (iSMKO) and assessed lesion development in the brachiocephalic artery (BCA) of tamoxifen vs. vehicle injected iSMKO mice on a Western diet (WD) for 15 or 40 weeks. In BCAs of iSMKO mice, lesion size and relative stenosis were increased and lumenal area decreased compared to vehicle injected mice. Additionally, iSMKO mice exhibited a significant reduction in SMC and collagen content at 15 weeks and 40 weeks, while macrophage content increased at 40 weeks. RNAseq analysis of BCA samples from tamoxifen and vehicle injected iSMKO mice prior to WD feeding (baseline) indicated increased mitochondrial function and PPAR-dependent signaling, similar to that found in prior studies of global KCa3.1 silencing. However, following 15 weeks of WD and induction of disease, these differences were no longer observed. Overall, this study provides the first cell-specific silencing of KCa3.1 to elucidate the contribution of KCa3.1 in smooth muscle to prior observations of KCa3.1 silencing. Our findings reveal both a beneficial role of SMC KCa3.1 in limiting plaque size and macrophage infiltration, and a potentially detrimental effect of reducing plaque SMC and collagen content. Combined with previous studies, this raises caution in the use of pharmacological KCa3.1 inhibitors in atherosclerosis and highlights the need for cell-specific targeting of KCa3.1 in optimizing potential therapies.

bioRxiv (Cold Spring Harbor Laboratory)
University of Missouri (US)
American Heart Association, National Institutes of Health
Good health and well-being
Atherosclerosis and Cardiovascular Diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon